Is the application of flexibility in decision-making proof of the system's strength or the inherent weakness in our approach to HTA? Does there need to be transparency and consistency in its application or do we risk undermining the system's equity?
Is flexibility a sign of the system's strength or does it expose a weakness?
July 26, 2019 Latest News
Latest Video
New Stories
-
Omico opens a new chapter in precision oncology research
June 1, 2026 - - Latest News -
Ex-MA executive named the first CEO of Medicinal Cannabis Council Australia
June 1, 2026 - - Latest News -
Oral RAS inhibitor doubles median survival and cuts death risk in metastatic pancreatic cancer
June 1, 2026 - - Latest News -
Australia risks losing more than jobs in its biopharmaceutical sector — it risks losing strategic capability
June 1, 2026 - - Latest News -
New PBS listings expand access to blood cancer therapies
June 1, 2026 - - Latest News -
Now you can see the next step in the process most are officially excluded from
June 1, 2026 - - Latest News -
Australia's HTA Review closed-loop process continues with 'Delphi' stage two
June 1, 2026 - - Latest News
